Patents by Inventor Linrong Lu

Linrong Lu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of chimeric antigen receptor modified cells to treat autoimmune disease
    Patent number: 11690874
    Abstract: Embodiments of the present disclosure include a method for treating Systemic Lupus Erythematosus (SLE) using CD19 CAR T cells. The method includes administering to the human patient a pharmaceutically effective amount of a population of T cells of the human patient that express a chimeric antigen receptor (CAR) that comprises the amino acid sequence of, e.g., SEQ ID NO: 23.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: July 4, 2023
    Assignees: Innovative Cellular Therapeutics Holdings, Ltd., Zhejiang University
    Inventors: Lei Xiao, Chengfei Pu, Zhao Wu, Linrong Lu
  • Discovery of regulatory T cells programmed to suppress an immune response
    Patent number: 10596195
    Abstract: A method to treat an autoimmune disease is provided. The method involves administration of interleukin-15 receptor (IL-15R) agonists in an amount effective to ameliorate a symptom of the autoimmune disease. The invention also involves a method to treat an autoimmune disease by ex-vivo expansion of CD44+CD122+Kir+ CD8+ Treg cells and administration of the CD44+CD122+Kir+ CD8+ Treg cells. Compositions comprising CD44+CD122+Kir+ CD8+ Treg cells are also provided. Methods for stimulating an immune response to an antigen are also provided.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: March 24, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Harvey Cantor, Hye-Jung Kim, Linrong Lu
  • Use of Chimeric Antigen Receptor Modified Cells to Treat Autoimmune Disease
    Publication number: 20200078403
    Abstract: Embodiments of the present disclosure include a method for treating Systemic Lupus Erythematosus (SLE) using CD19 CAR T cells. The method includes administering to the human patient a pharmaceutically effective amount of a population of T cells of the human patient that express a chimeric antigen receptor (CAR) that comprises the amino acid sequence of, e.g., SEQ ID NO: 23.
    Type: Application
    Filed: September 12, 2019
    Publication date: March 12, 2020
    Applicants: INNOVATIVE CELLULAR THERAPEUTICS CO., LTD., ZHEJIANG UNIVERSITY
    Inventors: LEI XIAO, CHENGFEI PU, ZHAO WU, LINRONG LU
  • DISCOVERY OF REGULATORY T CELLS PROGRAMMED TO SUPPRESS AN IMMUNE RESPONSE
    Publication number: 20170224732
    Abstract: A method to treat an autoimmune disease is provided. The method involves administration of interleukin-15 receptor (IL-15R) agonists in an amount effective to ameliorate a symptom of the autoimmune disease. The invention also involves a method to treat an autoimmune disease by ex-vivo expansion of CD44+CD122+Kir+ CD8+ Treg cells and administration of the CD44+CD122+Kir+ CD8+ Treg cells. Compositions comprising CD44+CD122+Kir+ CD8+ Treg cells are also provided. Methods for stimulating an immune response to an antigen are also provided.
    Type: Application
    Filed: January 13, 2017
    Publication date: August 10, 2017
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Harvey Cantor, Hye-Jung Kim, Linrong Lu
  • DISCOVERY OF REGULATORY T CELLS PROGRAMMED TO SUPPRESS AN IMMUNE RESPONSE
    Publication number: 20130302276
    Abstract: A method to treat an autoimmune disease is provided. The method involves administration of interleukin-15 receptor (IL-15R) agonists in an amount effective to ameliorate a symptom of the autoimmune disease. The invention also involves a method to treat an autoimmune disease by ex-vivo expansion of CD44+CD122+Kir+ CD8+ Treg cells and administration of the CD44+CD122+Kir+ CD8+ Treg cells. Compositions comprising CD44+CD122+Kir+ CD8+ Treg cells are also provided. Methods for stimulating an immune response to an antigen are also provided.
    Type: Application
    Filed: October 18, 2011
    Publication date: November 14, 2013
    Applicant: DANA-FARBER CANCER INSITUTE INC.,
    Inventors: Harvey Cantor, Hye-Jung Kim, Linrong Lu